Arkolith/Insider Trading/BTTX/Form 4

Zamirowski Justin

Chief Commercial OfficerBetter Therapeutics, Inc. (BTTX) · full profile →Form 4 · filed May 18, 2022
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
1 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 16, 2022Option exercise(M)35K$0.50$18K35K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 16, 2022Option exercise(M)35K—$045K

Transaction Codes

M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000899243-22-018628) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML